½ÃÀ庸°í¼­
»óǰÄÚµå
1544287

¼¼°èÀÇ Èñ±Í Ç÷¿ìº´ ÀÎÀÚ ½ÃÀå(2024-2028³â)

Global Rare Hemophilia Factors Market 2024-2028

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: TechNavio | ÆäÀÌÁö Á¤º¸: ¿µ¹® 142 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Èñ±Í Ç÷¿ìº´ ÀÎÀÚ ½ÃÀåÀº 2023-2028³â 2¾ï 860¸¸ ´Þ·¯ ±Ô¸ð·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È ¿¬Æò±Õ 10.04%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ º¸°í¼­´Â Èñ±Í Ç÷¿ìº´ ÀÎÀÚ ½ÃÀå¿¡ ´ëÇÑ Àü¹ÝÀûÀÎ ºÐ¼®, ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, µ¿Çâ, ¼ºÀå ÃËÁø¿äÀÎ, °úÁ¦, ¾à 25°³ º¥´õ¿¡ ´ëÇÑ º¥´õ ºÐ¼® µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.

ÇöÀç ½ÃÀå ½Ã³ª¸®¿À, Ãֽе¿Çâ ¹× ÃËÁø¿äÀÎ, Àüü ½ÃÀå ȯ°æ¿¡ ´ëÇÑ ÃֽŠºÐ¼®À» Á¦°øÇÕ´Ï´Ù. ÀÌ ½ÃÀåÀº »õ·Î¿î Ä¡·á ±â¼úÀÇ ½ÂÀÎ, ºñ¿ë È¿À²ÀûÀÌ°í °íǰÁúÀÇ ÀÇ·á ¼Ö·ç¼ÇÀÇ Ã¤ÅÃ, Á¤ºÎÀÇ Àû±ØÀûÀÎ ³ë·Â µî¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¹üÀ§
±âÁØ ¿¬µµ 2024³â
Á¾·á ¿¬µµ 2028³â
¿¹Ãø ±â°£ 2024-2028³â
¼ºÀå ¸ð¸àÅÒ °¡¼Ó
Àü³â ´ëºñ[2024³â] 8.88%
CAGR 10.04%
ÁõºÐ ±Ý¾× 2¾ï 860¸¸ ´Þ·¯

ÀÌ º¸°í¼­´Â À¯ÀüÀÚ Ä¡·áÀÇ µîÀåÀÌ ÇâÈÄ ¸î ³â µ¿¾È Èñ±Í Ç÷¿ìº´ ÀÎÀÚ ½ÃÀå ¼ºÀåÀ» ÁÖµµÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß Çϳª¶ó°í ºÐ¼®Çß½À´Ï´Ù. ¶ÇÇÑ, Ä¡·á¹ý °³¹ßÀ» À§ÇÑ ±â¼ú Çõ½Å°ú »õ·Î¿î Àü·«¿¡ ´ëÇÑ R&DÀÇ Áõ°¡´Â ½ÃÀåÀÇ Å« ¼ö¿ä·Î À̾îÁú °ÍÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå °³¿ä

Á¦2Àå ½ÃÀå »óȲ

  • ½ÃÀå »ýŰè
  • ½ÃÀåÀÇ Æ¯Â¡
  • ¹ë·ùüÀÎ ºÐ¼®

Á¦3Àå ½ÃÀå ±Ô¸ð Æò°¡

  • ½ÃÀå Á¤ÀÇ
  • ½ÃÀå ºÎ¹® ºÐ¼®
  • ½ÃÀå ±Ô¸ð 2023³â
  • ½ÃÀå Àü¸Á 2023-2028³â

Á¦4Àå ½ÃÀå ±Ô¸ð ½ÇÀû

  • Èñ±Í Ç÷¿ìº´ ÀÎÀÚ ¼¼°è ½ÃÀå 2018-2022³â
  • ¹æ¹ýº° ºÎ¹® ºÐ¼® 2018-2022³â
  • Áö¿ªº° ºÎ¹® ºÐ¼® 2018-2022³â
  • ±¹°¡º° ºÎ¹® ºÐ¼® 2018-2022³â

Á¦5Àå Five Forces ºÐ¼®

  • Five Forces ¿ä¾à
  • ±¸¸ÅÀÚÀÇ ±³¼··Â
  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù
  • °æÀïÀÇ À§Çù
  • ½ÃÀå »óȲ

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­ : ¹æ¹ýº°

  • ½ÃÀå ¼¼ºÐÈ­
  • ºñ±³ : ¹æ¹ýº°
  • ½Å¼± µ¿°á Ç÷Àå : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
  • ÀÎÀÚ ³óÃ๰ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
  • µ¿°áħÀüÁ¦Á¦ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
  • ±âŸ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
  • ½ÃÀå ±âȸ : ¹æ¹ýº°

Á¦7Àå °í°´ »óȲ

  • °í°´ »óȲ °³¿ä

Á¦8Àå Áö¿ªº° »óȲ

  • Áö¿ªº° ¼¼ºÐÈ­
  • ºñ±³ : Áö¿ªº°
  • ºÏ¹Ì : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
  • À¯·´ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
  • ¾Æ½Ã¾Æ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
  • ±âŸ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
  • ¹Ì±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
  • µ¶ÀÏ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
  • ¿µ±¹ : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
  • ij³ª´Ù : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
  • ÀϺ» : ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø 2023-2028³â
  • ½ÃÀå ±âȸ : Áö¿ª »óȲº°

Á¦9Àå ÃËÁø¿äÀÎ, °úÁ¦, ±âȸ, ¾ïÁ¦¿äÀÎ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå °úÁ¦
  • ¼ºÀå ÃËÁø¿äÀΰú °úÁ¦ÀÇ ¿µÇâ
  • ½ÃÀå ±âȸ¡¤¾ïÁ¦¿äÀÎ

Á¦10Àå °æÀï »óȲ

  • °³¿ä
  • °æÀï »óȲ
  • È¥¶õ »óȲ
  • ¾÷°è ¸®½ºÅ©

Á¦11Àå °æÀï ºÐ¼®

  • ±â¾÷ °³¿ä
  • ±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Å´×
  • Aptevo Therapeutics Inc.
  • Bayer AG
  • CSL Ltd.
  • F. Hoffmann La Roche Ltd.
  • Grifols SA
  • Novo Nordisk AS
  • Octapharma AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Co. Ltd.

Á¦12Àå ºÎ·Ï

ksm 24.09.09

The rare hemophilia factors market is forecasted to grow by USD 208.6 mn during 2023-2028, accelerating at a CAGR of 10.04% during the forecast period. The report on the rare hemophilia factors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by approval of new treatment techniques, introduction of cost-effective and high-quality medical solutions, and favorable government initiatives.

Technavio's rare hemophilia factors market is segmented as below:

Market Scope
Base Year2024
End Year2028
Series Year2024-2028
Growth MomentumAccelerate
YOY 20248.88%
CAGR10.04%
Incremental Value$208.6 mn

By Method

    • Fresh frozen plasma
    • Factor concentrates
    • Cryoprecipitate
    • Others

By Geographical Landscape

    • North America
    • Europe
    • Asia
    • Rest of World (ROW)

This study identifies the advent of gene therapy as one of the prime reasons driving the rare hemophilia factors market growth during the next few years. Also, increase in technological innovations and R and D of novel strategies to develop therapeutics will lead to sizable demand in the market.

The report on the rare hemophilia factors market covers the following areas:

    • Rare hemophilia factors market sizing
    • Rare hemophilia factors market forecast
    • Rare hemophilia factors market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading rare hemophilia factors market vendors that include Alnylam Pharmaceuticals Inc., Aptevo Therapeutics Inc., Bayer AG, Bio Products Laboratory Ltd., CSL Ltd., F. Hoffmann La Roche Ltd., Genentech Inc., Grifols SA, Gyre Therapeutics Inc., Intermountain Healthcare, Kedrion Spa, Novo Nordisk AS, Octapharma AG, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., The Johns Hopkins Health System Corp., UCSF Health, uniQure NV, and Versiti. Also, the rare hemophilia factors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

  • 1.1 Market overview
    • Executive Summary - Chart on Market Overview
    • Executive Summary - Data Table on Market Overview
    • Executive Summary - Chart on Global Market Characteristics
    • Executive Summary - Chart on Market By Geographical Landscape
    • Executive Summary - Chart on Market Segmentation by Method
    • Executive Summary - Chart on Incremental Growth
    • Executive Summary - Data Table on Incremental Growth
    • Executive Summary - Chart on Company Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Parent Market
    • Data Table on - Parent Market
  • 2.2 Market characteristics
    • Market characteristics analysis
  • 2.3 Value chain analysis
    • Value Chain Analysis

3 Market Sizing

  • 3.1 Market definition
    • Offerings of companies included in the market definition
  • 3.2 Market segment analysis
    • Market segments
  • 3.3 Market size 2023
  • 3.4 Market outlook: Forecast for 2023-2028
    • Chart on Global - Market size and forecast 2023-2028 ($ million)
    • Data Table on Global - Market size and forecast 2023-2028 ($ million)
    • Chart on Global Market: Year-over-year growth 2023-2028 (%)
    • Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

  • 4.1 Global Rare Hemophilia Factors Market 2018 - 2022
    • Historic Market Size - Data Table on Global Rare Hemophilia Factors Market 2018 - 2022 ($ million)
  • 4.2 Method segment analysis 2018 - 2022
    • Historic Market Size - Method Segment 2018 - 2022 ($ million)
  • 4.3 Geography segment analysis 2018 - 2022
    • Historic Market Size - Geography Segment 2018 - 2022 ($ million)
  • 4.4 Country segment analysis 2018 - 2022
    • Historic Market Size - Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

  • 5.1 Five forces summary
    • Five forces analysis - Comparison between 2023 and 2028
  • 5.2 Bargaining power of buyers
    • Bargaining power of buyers - Impact of key factors 2023 and 2028
  • 5.3 Bargaining power of suppliers
    • Bargaining power of suppliers - Impact of key factors in 2023 and 2028
  • 5.4 Threat of new entrants
    • Threat of new entrants - Impact of key factors in 2023 and 2028
  • 5.5 Threat of substitutes
    • Threat of substitutes - Impact of key factors in 2023 and 2028
  • 5.6 Threat of rivalry
    • Threat of rivalry - Impact of key factors in 2023 and 2028
  • 5.7 Market condition
    • Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Method

  • 6.1 Market segments
    • Chart on Method - Market share 2023-2028 (%)
    • Data Table on Method - Market share 2023-2028 (%)
  • 6.2 Comparison by Method
    • Chart on Comparison by Method
    • Data Table on Comparison by Method
  • 6.3 Fresh frozen plasma - Market size and forecast 2023-2028
    • Chart on Fresh frozen plasma - Market size and forecast 2023-2028 ($ million)
    • Data Table on Fresh frozen plasma - Market size and forecast 2023-2028 ($ million)
    • Chart on Fresh frozen plasma - Year-over-year growth 2023-2028 (%)
    • Data Table on Fresh frozen plasma - Year-over-year growth 2023-2028 (%)
  • 6.4 Factor concentrates - Market size and forecast 2023-2028
    • Chart on Factor concentrates - Market size and forecast 2023-2028 ($ million)
    • Data Table on Factor concentrates - Market size and forecast 2023-2028 ($ million)
    • Chart on Factor concentrates - Year-over-year growth 2023-2028 (%)
    • Data Table on Factor concentrates - Year-over-year growth 2023-2028 (%)
  • 6.5 Cryoprecipitate - Market size and forecast 2023-2028
    • Chart on Cryoprecipitate - Market size and forecast 2023-2028 ($ million)
    • Data Table on Cryoprecipitate - Market size and forecast 2023-2028 ($ million)
    • Chart on Cryoprecipitate - Year-over-year growth 2023-2028 (%)
    • Data Table on Cryoprecipitate - Year-over-year growth 2023-2028 (%)
  • 6.6 Others - Market size and forecast 2023-2028
    • Chart on Others - Market size and forecast 2023-2028 ($ million)
    • Data Table on Others - Market size and forecast 2023-2028 ($ million)
    • Chart on Others - Year-over-year growth 2023-2028 (%)
    • Data Table on Others - Year-over-year growth 2023-2028 (%)
  • 6.7 Market opportunity by Method
    • Market opportunity by Method ($ million)
    • Data Table on Market opportunity by Method ($ million)

7 Customer Landscape

  • 7.1 Customer landscape overview
    • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

8 Geographic Landscape

  • 8.1 Geographic segmentation
    • Chart on Market share By Geographical Landscape 2023-2028 (%)
    • Data Table on Market share By Geographical Landscape 2023-2028 (%)
  • 8.2 Geographic comparison
    • Chart on Geographic comparison
    • Data Table on Geographic comparison
  • 8.3 North America - Market size and forecast 2023-2028
    • Chart on North America - Market size and forecast 2023-2028 ($ million)
    • Data Table on North America - Market size and forecast 2023-2028 ($ million)
    • Chart on North America - Year-over-year growth 2023-2028 (%)
    • Data Table on North America - Year-over-year growth 2023-2028 (%)
  • 8.4 Europe - Market size and forecast 2023-2028
    • Chart on Europe - Market size and forecast 2023-2028 ($ million)
    • Data Table on Europe - Market size and forecast 2023-2028 ($ million)
    • Chart on Europe - Year-over-year growth 2023-2028 (%)
    • Data Table on Europe - Year-over-year growth 2023-2028 (%)
  • 8.5 Asia - Market size and forecast 2023-2028
    • Chart on Asia - Market size and forecast 2023-2028 ($ million)
    • Data Table on Asia - Market size and forecast 2023-2028 ($ million)
    • Chart on Asia - Year-over-year growth 2023-2028 (%)
    • Data Table on Asia - Year-over-year growth 2023-2028 (%)
  • 8.6 Rest of World (ROW) - Market size and forecast 2023-2028
    • Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
    • Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
    • Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
    • Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
  • 8.7 US - Market size and forecast 2023-2028
    • Chart on US - Market size and forecast 2023-2028 ($ million)
    • Data Table on US - Market size and forecast 2023-2028 ($ million)
    • Chart on US - Year-over-year growth 2023-2028 (%)
    • Data Table on US - Year-over-year growth 2023-2028 (%)
  • 8.8 Germany - Market size and forecast 2023-2028
    • Chart on Germany - Market size and forecast 2023-2028 ($ million)
    • Data Table on Germany - Market size and forecast 2023-2028 ($ million)
    • Chart on Germany - Year-over-year growth 2023-2028 (%)
    • Data Table on Germany - Year-over-year growth 2023-2028 (%)
  • 8.9 UK - Market size and forecast 2023-2028
    • Chart on UK - Market size and forecast 2023-2028 ($ million)
    • Data Table on UK - Market size and forecast 2023-2028 ($ million)
    • Chart on UK - Year-over-year growth 2023-2028 (%)
    • Data Table on UK - Year-over-year growth 2023-2028 (%)
  • 8.10 Canada - Market size and forecast 2023-2028
    • Chart on Canada - Market size and forecast 2023-2028 ($ million)
    • Data Table on Canada - Market size and forecast 2023-2028 ($ million)
    • Chart on Canada - Year-over-year growth 2023-2028 (%)
    • Data Table on Canada - Year-over-year growth 2023-2028 (%)
  • 8.11 Japan - Market size and forecast 2023-2028
    • Chart on Japan - Market size and forecast 2023-2028 ($ million)
    • Data Table on Japan - Market size and forecast 2023-2028 ($ million)
    • Chart on Japan - Year-over-year growth 2023-2028 (%)
    • Data Table on Japan - Year-over-year growth 2023-2028 (%)
  • 8.12 Market opportunity By Geographical Landscape
    • Market opportunity By Geographical Landscape ($ million)
    • Data Tables on Market opportunity By Geographical Landscape ($ million)

9 Drivers, Challenges, and Opportunity/Restraints

  • 9.1 Market drivers
  • 9.2 Market challenges
  • 9.3 Impact of drivers and challenges
    • Impact of drivers and challenges in 2023 and 2028
  • 9.4 Market opportunities/restraints

10 Competitive Landscape

  • 10.1 Overview
  • 10.2 Competitive Landscape
    • Overview on criticality of inputs and factors of differentiation
  • 10.3 Landscape disruption
    • Overview on factors of disruption
  • 10.4 Industry risks
    • Impact of key risks on business

11 Competitive Analysis

  • 11.1 Companies profiled
    • Companies covered
  • 11.2 Market positioning of companies
    • Matrix on companies position and classification
  • 11.3 Aptevo Therapeutics Inc.
    • Aptevo Therapeutics Inc. - Overview
    • Aptevo Therapeutics Inc. - Product / Service
    • Aptevo Therapeutics Inc. - Key offerings
  • 11.4 Bayer AG
    • Bayer AG - Overview
    • Bayer AG - Business segments
    • Bayer AG - Key news
    • Bayer AG - Key offerings
    • Bayer AG - Segment focus
  • 11.5 CSL Ltd.
    • CSL Ltd. - Overview
    • CSL Ltd. - Business segments
    • CSL Ltd. - Key news
    • CSL Ltd. - Key offerings
    • CSL Ltd. - Segment focus
  • 11.6 F. Hoffmann La Roche Ltd.
    • F. Hoffmann La Roche Ltd. - Overview
    • F. Hoffmann La Roche Ltd. - Business segments
    • F. Hoffmann La Roche Ltd. - Key news
    • F. Hoffmann La Roche Ltd. - Key offerings
    • F. Hoffmann La Roche Ltd. - Segment focus
  • 11.7 Grifols SA
    • Grifols SA - Overview
    • Grifols SA - Business segments
    • Grifols SA - Key news
    • Grifols SA - Key offerings
    • Grifols SA - Segment focus
  • 11.8 Novo Nordisk AS
    • Novo Nordisk AS - Overview
    • Novo Nordisk AS - Business segments
    • Novo Nordisk AS - Key news
    • Novo Nordisk AS - Key offerings
    • Novo Nordisk AS - Segment focus
  • 11.9 Octapharma AG
    • Octapharma AG - Overview
    • Octapharma AG - Product / Service
    • Octapharma AG - Key offerings
  • 11.10 Pfizer Inc.
    • Pfizer Inc. - Overview
    • Pfizer Inc. - Product / Service
    • Pfizer Inc. - Key news
    • Pfizer Inc. - Key offerings
  • 11.11 Sanofi SA
    • Sanofi SA - Overview
    • Sanofi SA - Business segments
    • Sanofi SA - Key news
    • Sanofi SA - Key offerings
    • Sanofi SA - Segment focus
  • 11.12 Takeda Pharmaceutical Co. Ltd.
    • Takeda Pharmaceutical Co. Ltd. - Overview
    • Takeda Pharmaceutical Co. Ltd. - Product / Service
    • Takeda Pharmaceutical Co. Ltd. - Key news
    • Takeda Pharmaceutical Co. Ltd. - Key offerings

12 Appendix

  • 12.1 Scope of the report
  • 12.2 Inclusions and exclusions checklist
    • Inclusions checklist
    • Exclusions checklist
  • 12.3 Currency conversion rates for US$
    • Currency conversion rates for US$
  • 12.4 Research methodology
    • Research methodology
  • 12.5 Data procurement
    • Information sources
  • 12.6 Data validation
    • Data validation
  • 12.7 Validation techniques employed for market sizing
    • Validation techniques employed for market sizing
  • 12.8 Data synthesis
    • Data synthesis
  • 12.9 360 degree market analysis
    • 360 degree market analysis
  • 12.10 List of abbreviations
    • List of abbreviations
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦